Amgen recently announced that it has granted a platinum sponsorship to QB3@953 life science incubator to speed the creation of innovative treatments that will improve the health of patients.
This sponsorship, which will last for five years, is specifically for the QB3@953 shared laboratory space. The goal is to encourage high-potential life science and biotech startups to surpass one of the main challenges that faces early stage companies: laboratory infrastructure.
"The QB3@953 Amgen Golden Ticket award supports our research and development strategy to fund early-stage innovation in the biotech hubs of San Francisco and Cambridge, Massachusetts," Flavius Martin, vice president of research, inflammation and oncology at Amgen, said. "It's critical to the future of healthcare to support promising scientific entrepreneurs. It's rewarding to be part of the energy and enthusiasm of scientific entrepreneurs in this early stage, and to help accelerate the momentum of advancements in human health."
In addition, the Amgen Gold Ticket awards will grant the winners a year of space at the QB3@953 lab.
"We are delighted to facilitate the connection with Amgen, one of the world's leading biotechnology companies, with the entrepreneurs at QB3@953," Doug Crawford, managing director at QB3@953, said. "Being chosen as the Amgen Golden Ticket winner brings a prestige that resonates with the scientific community in addition to the lab resources, scientific and business expertise that Amgen provides."
